Imiquimod D7
| Product Name | Imiquimod D7 |
|---|---|
| Alternate Names | Imiquimod Stable Isotopes, Stable Isotopes of Imiquimod |
| CAT No. | CS-O-10005 |
| CAS No. | 99011-02-6(Unlabeled) |
| Category | Stable Isotopes |
| Stock | IN-Stock |
| Mol. Wt. | 247.35 g/mol |
| Mol. For. | C14H9D7N4 |
| Hazardous | This is a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Imiquimod |
| Purity | 95% |
| Therapeutic | Antiretroviral / Anti-HIV |
| Smileys | NC1=C2C(N(C=N2)CC(C([2H])([2H])[2H])([2H])C([2H])([2H])[2H])=C(C=CC=C3)C3=N1 |
| Canonical Smiles | CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N |
| InchIKey | DOUYETYNHWVLEO-UHFFFAOYSA-N |
| Inchl | InChI=1S/C14H16N4/c1-9(2)7-18-8-16-12-13(18)10-5-3-4-6-11(10)17-14(12)15/h3-6,8-9H,7H2,1-2H3,(H2,15,17) |
| IUPAC | 1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Imiquimod D7 is a synthetic and deuterated analogue of the immune response modifier Imiquimod. It is commonly used to treat external genital and perianal warts caused by human papillomavirus (HPV), as well as actinic keratosis, superficial basal cell carcinoma, and other skin conditions.
The mechanism of action of Imiquimod D7 involves activation of the immune system, particularly the innate immune system, to produce cytokines and chemokines that stimulate the immune response against viral and cancerous cells. This immune response results in the destruction of the infected or abnormal cells.
Imiquimod D7 is applied topically to the affected area and is typically used for several weeks until the condition resolves. It is available as a 5% cream or a 3.75% pump. It should not be used on open wounds or mucous membranes, and caution should be used when applying it near the eyes.
Imiquimod D7 is metabolized in the liver and excreted primarily in the urine. It has a half-life of approximately 10 hours and is eliminated from the body within 24 hours of application. It has no significant drug interactions, and there is no evidence of systemic toxicity with normal use.
In conclusion, Imiquimod D7 is a safe and effective treatment option for various skin conditions, particularly those caused by HPV. Its unique mechanism of action and minimal side effects make it a popular choice for dermatologists and patients alike.
Get an Instant Quote
Related Compounds
Imiquimod-d9 |